Merger includes C$20 million investment to accelerate access to genomics-based testing for cancer treatment by combining Canexia Health’s advanced molecular cancer solutions with Imagia Cybernetics’ healthcare and AI expertise
April 21, 2022
Vancouver, BC [April 21, 2022] – Canada’s Digital Technology Supercluster is excited to be
December 13, 2021
With a strategic investment from Canada’s Digital Technology Supercluster, a pilot project to bring ctDNA testing into the Canadian health system was launched in July 2020.
November 11, 2021
Liquid biopsy is a powerful tool for matching cancer patients with targeted therapies and for cancer recurrence monitoring.
November 4, 2021
The use of genomic profiling and testing in cancer is helping clinicians and patients better understand the key drivers of a patient’s tumour and inform more precise treatment decisions.
November 1, 2021
FOUNTAIN VALLEY, Calif.
September 14, 2021
OncoHelix and Canexia Health, are partnering to help Canadian cancer patients gain access to precision genomic testing via their oncologist. Using a circulating tumour DNA (ctDNA) or “liquid biopsy” blood sample, the partnership allows for Canexia Health’s Follow It® ctDNA 38-gene panel to be accessed through OncoHelix for testing services.
May 19, 2021
The California health system is working with Canexia to assess if a triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.
March 11, 2021
If we are to minimize the now well-documented burdens of COVID-19 on cancer patients, governments must support innovations that improve their outcomes and cut through the healthcare roadblocks posed by the pandemic.
Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.